Webinar: Single B Cell Platforms for Rapid Antibody Discovery

Single B cell antibody discovery technology is a powerful and versatile platform for rapidly isolating and characterizing high-quality antibodies from individual B cells. By leveraging microfluidics and high-throughput sequencing, this method enables the efficient screening and cloning of antibodies with high specificity and affinity, directly from immunized hosts. Compared to traditional hybridoma and phage display technologies, our single B cell platform offers significant advantages: a dramatically shorter discovery cycle (often within days to weeks), preservation of natural heavy and light chain pairing, and access to a broader diversity of native antibodies.

The single B cell platform demonstrates remarkable versatility across species. It proves exceptionally efficient for producing alpaca-derived single-domain antibodies (VHHs/nanobodies), which are characterized by their compact size, enhanced stability, and superior tissue penetration—ideal properties for engaging complex epitopes. The seamless, integrated workflow, spanning from B cell sorting to lead characterization, establishes a streamlined pipeline for identifying potent therapeutic candidates, underscoring the platform's role as a comprehensive solution for next-generation antibody discovery.

Key Points

1. Single B Cell Platform: Bypassing traditional hybridoma to capture diverse, native-paired antibodies

2. Rapid Murine mAb Discovery: Case examples demonstrating the speed and success of CUSABIO platform

3. Alpaca VHH Development: Leveraging Single B Cell Technology for Enhanced Nanobody Discovery

Webinar Registration

The webinar will be held three to accommodate our global audience.

November 5, 2025 3:30 pm JST/KST

November 5, 2025 2:00 pm CET

November 5, 2025 11:00 am PDT/ 2:00 pm EDT

Speaker

Ying Zhou PhD

Product Manager, CUSABIO

Join Dr. Ying Zhou, Product Manager at CUSABIO, as she unveils the potential of DT3C to transform ADC development and improve cancer treatment outcomes.